Skip to main content

Specialty Labs to Use Celera Genomic Data for Cirrhosis Test

NEW YORK, June 22 (GenomeWeb News) - Specialty Laboratories will use Celera Genomics' genetic data to develop a test to predict the risk for patients with hepatitis C virus of developing liver cirrhosis, the companies said today in a statement.

 

Specialty will pay Celera an upfront fee after it has validated a test, and it will pay Celera royalties on net sales in the United States, according to the statement. The companies did not disclose further financial details.

 

The companies believe a genetic test may be useful for a larger number of HCV-infected patients than currently used methods, Celera and Specialty said.

 

"Currently, there is an unmet medical need for a predictive method to determine which patients with chronic HCV are likely to develop fibrosis and progression to cirrhosis," said James Peter, founder and chairman of Specialty, in a statement.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.